CheckMate 649 (97) is a global, multicenter, randomized phase III trial that assessed the efficacy of nivolumab combined with chemotherapy as a first-line treatment for HER2-negative, advanced or metastatic GC, GEJC, and esophageal cancer (EC). This evidence concerns the gene ERBB2 and gastric cancer.